PD-L1 testing for lung cancer in the UK: recognizing the challenges for implementation. Histopathology 2016;69:177-86.Cree, I.A., et al., PD-L1 testing for lung cancer in the UK: recognizing the challenges for implementation. Histopathology, 2016. 69(2): p. 177-86....
PD-L1 IHC检测的结果报告中除了常规病理报告中的基本信息外,还应包括标本信息、PD-L1检测流程相关信息以及PD-L1检测结果三部分。标本信息包括采集部位、标本类型、蜡块存储时间以及脱钙情况等;PD-L1检测流程相关信息包括PD-L1检测所用平台、...
PD-L1 IHC检测的结果报告中除了常规病理报告中的基本信息外,还应包括标本信息、PD-L1检测流程相关信息以及PD-L1检测结果三部分。标本信息包括采集部位、标本类型、蜡块存储时间以及脱钙情况等;PD-L1检测流程相关信息包括PD-L1检测所用平台、PD-L1检测所用抗体克隆号以及检测标本质控等;PD-L1检测结果包括PD-L1表达相...
文献或会议报道中常简称PD-L1(SP142)或SP142,临床中主要用于免疫治疗最具代表的PD-1/PD-L1免疫检查点抑制剂相关适应症治疗决策时疗效预测,是现阶段临床实践中经试验验证、法规审批的疗效预测标志物之一[5-7]。
[4] 陈晓童. PD-L1 临床免疫组织化学检测新进展[J]. 世界最新医学信息文摘, 2018, 18(17): 21-22. [5] Tsao MS, Kerr KM, Dacic S,et al. IASLC Atlas of PD-L1 Immunohistochemistry testing in lung cancer. 1st ed. Aurora: International Association for the Study of Lung Cancer, 2017....
免疫组织化学(immunohistochemistry,IHC,简称免疫组化)检测是评估肿瘤组织PD-L1表达状态的一种有效且最常用方法,广泛应用于包括非小细胞肺癌(non-small cell lung cancer, NSCLC)等在内的多种恶性肿瘤中,以识别或辅助预测可能从免疫治疗中获益的患者。 为更好地指导临床检测,中国抗癌协会肿瘤病理专业委员会肺癌学组...
[11]. Aguiar PN Jr, et al. PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data. Immunotherapy. 2017;9(6):499-506. [12]. 中国临床肿瘤学会(CSCO)非小细胞肺癌诊疗指南2020版. [13]. Lantuejoul S, et al. PD-L1 Testing for Lung Canc...
Grigg and Rizvi Journal for ImmunoTherapy of Cancer (2016) 4:48 DOI 10.1186/s40425-016-0153-x CLINICAL TRIALS MONITOR PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction? Claud Grigg* and Naiyer A. Rizvi Open Access Abstract Research in cancer immunology is currently ...
肿瘤浸润性免疫细胞、突变负荷、基因特征等都是筛选患者的指标,但在没有精准的分选系统出炉前,临床实践中想知道哪些患者对PD-1抑制剂治疗最有效,还是靠PD-L1检测。 文献:Aaron Lisberg.et al.TheValue of PD-L1 Testing in Non–Small-Cell Lung Cancer.March 17, 2016.JAMAOncology. ...
Impact of Specimen Characteristics on PD-L1 Testing in Non-Small Cell Lung Cancer: Validation of the IASLC PD-L1 Testing Recommendations Introduction: Molecules targeting programmed cell death 1 or its ligand programmed death ligand 1 (PD-L1) revolutionized the treatment of patients with NSC... Ga...